Jan 22 (Reuters) - Immutep Ltd IMM.AX :
* ULCERATIVE COLITIS PHASE II STUDY OF GSK2831781 DISCONTINUED
* IMMUTEP'S COLLABORATION AND EXCLUSIVE LICENSE WITH GSK REMAINS IN PLACE
* TRIAL STOPPED BY GSK BASED ON ASSESSMENT OF CLINICAL DATA AS PART OF ANALYSIS IN CONSULTATION WITH DATA REVIEW COMMITTEE
* DISCONTINUATION OF GSK TRIAL HAS NO IMPACT ON CO'S THREE OTHER PRODUCT CANDIDATES
* UNDER AGREEMENT CO ELIGIBLE FOR UP TO £54 MILLION IN REMAINING DEVELOPMENTAL MILESTONE PAYMENTS & OTHER ROYALTIES, IF GSK2831781 IS COMMERCIALISED
* NO IMPACT TO FUNDING CAPACITY FOR DEVELOPMENT OF ITS IN-HOUSE PROGRAMS